1. Home /
  2. Biotechnology

Biotechnology

Gilead Sciences Expected to Earn $1.61 a Share

Gilead Sciences Expected to Earn $1.61 a Share

Gilead Sciences revenue expected to rise 4.1% to $5.3 billion.

Amgen's First-Quarter Earnings Slump as Expenses Jump

Amgen's First-Quarter Earnings Slump as Expenses Jump

Adjusted earnings of $3.56 a share in the quarter topped analysts' expectations.

News Surrounds 3 Small Biotechs, With a Merger Claiming One

News Surrounds 3 Small Biotechs, With a Merger Claiming One

Two companies in pet pharmaceuticals plan to combine, while two other concerns are worth a look based on developments in their respective spaces.

Biogen Shares Fall After Drugmaker Meets Earnings Estimates

Biogen Shares Fall After Drugmaker Meets Earnings Estimates

The stock dips after the drugmaker beats quarterly revenue estimates and earnings meet forecasts.

CannTrust Shares Recover After Preliminary Quarterly Loss, New Share Issuance

CannTrust Shares Recover After Preliminary Quarterly Loss, New Share Issuance

Shares of Canadian cannabis-products maker CannTrust drop, then rebound, after the company reveals a preliminary quarterly loss and announces new share issuance.

A Tough Week for Biotech, the Candidates' Whipping Boy Again

A Tough Week for Biotech, the Candidates' Whipping Boy Again

Talk among a mammoth field of presidential candidates about drug price controls and an expansion of Medicare isn't helping biotech and health care stocks.

Amgen: This Beaten Down Blue Chip Is Priced To Own

Amgen: This Beaten Down Blue Chip Is Priced To Own

As the healthcare sector sells off, it's time to look for attractive value. You don't have to go any further than Amgen.

Danaher's Earnings Drop on GE Biopharma Acquisition Costs

Danaher's Earnings Drop on GE Biopharma Acquisition Costs

Danaher reports first-quarter earnings that beat analysts' estimates though revises forward guidance on costs related to acquisition of GE's biopharma business.

10 Speculative Stock Plays in the Biotech Sector

10 Speculative Stock Plays in the Biotech Sector

For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.

These 2 Biotech Stocks Are No Longer 'Off the Radar'

These 2 Biotech Stocks Are No Longer 'Off the Radar'

Few parts of the market have more volatility than the small caps in this sector.